National and international experts and specialists in addition to attending the Third International Pediatric Oncology Congress in Memory of Prof. Parvaneh Vossough, expressed their views on the MAHAK Pediatric Cancer Treatment and Research Center (MPCTRC).
Dr. Trish Scanlan, hematologist and oncologist from Ireland: MAHAK's activities are amazing. I have been working in Tanzania for 12 years and before visiting MAHAK I thought my activities were great. MAHAK's efforts for obviating obstacles of providing treatment and support services to cancer-stricken children and their families regardless of their financial status is a great factor. Moreover, MAHAK strives to resolve the psychological challenges which occur after their child is diagnosed with cancer so that the parents face with fewer challenges in the course of the treatment.
Prof. Dirk Reinhardt, pediatric hematologist and oncologist, University Hospital Essen, UK Essen: Exchanging knowledge and experiences between the specialists and medical students is one of the most important factors of this congress. In addition, doing joint research projects with MAHAK is among the conspicuous achievements of this congress. Undoubtedly, submitting papers by national and international experts results in more research projects and achieving fruitful scientific achievements.
Dr. Lana Tahir, hematologist and oncologist from Iraq: The acquisition of up-to-date modern science regarding cancer treatment makes it possible to compare medical practices with one another and, as a result, to benefit from new scientific research outcomes that are very useful for specialists in this field. MAHAK Hospital is a successful health care center and I hope that we will continue to hold such specialized events in different countries to improve the cancer treatment science.
Dr. Abdulrahman, hematologist and oncologist form Iraq: Providing treatment and support services to the cancer-stricken children is really precious. I hope that in future, by increasing the connection between the health centers of the region and MAHAK, we will see the improvement of the treatment performance and utilizing more effective methods in Iraqi Kurdistan.
Dr. Adnan, hematologist and oncologist from Iraq: MAHAK is a grateful organization.
In attending this congress, I became acquainted with the activities of MAHAK, and I see a brilliant future for this charity. I hope that with the continuation of such events, we will witness the presence of more specialists from the region to deliver lectures, such as practicing doctors in northern Iraq.
Prof. Ursula Creutzig, pediatric hematologist and oncologist, Department of Pediatric Hematology and Oncology, Hannover Medical School and a member of iBfm from Germany:
The outcome of this congress is impressive. Many of the therapeutic topics for the treatment of blood cancers such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and Non-hodgekin lymphoma (NHL) are presented with experimental examples with the presence of experts which will provide a deeper understanding of diagnosis, treatment and support services for all experts and specialists..
Prof. Jacqueline Cloos, Pediatric Hematology and Oncology Researcher at UVM University of Amsterdam: MAHAK, in line with its corporate social responsibility provides an opportunity for the medical students to take part in this congress which is a very important factor. Medical students are the future doctors and it's our responsibility to educate them to improve the medical science regarding in the field of cancer treatment. . Knowledge is a tool of power and we need to empower the enthusiasts of the field.
Prof. Roland Meisel, Pediatric Stem Cell Therapy Clinic for Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine-Universität Düsseldorf, HHU, Germany: Holding such scientific events will have a winning result for professionals from all over the world, and ultimately improve the treatment performance for children with cancer.
Dr. Naghmeh Niktoreh, Ph.D. student, University Children's Hospital Essen, University of Duisburg-Essen: Providing international relations with other countries, in addition to transferring knowledge and exchanging experiences, will motivate young researchers and students to conduct further research and focus on specialized topics. In other words, with the start of international cooperation and joint projects, we will see progress and new achievements in the field of cancer treatment.
Prof. Wilhelm Woessmann, Prof. Dr. med. Pediatric Hematology and Oncology, Department of Pediatric Hematology and Oncology, Justus-Liebig University, Giessen, Germany: Holding such a scientific event in the field of cancer provides a good platform for exchanging experiences, acquiring modern knowledge, being informed about new methods of treatment, and ultimately the recovery of children with cancer. MAHAK, as an NGO in Iran plays an indisputable role in the treatment of cancer-stricken children and improving their treatment conditions.
Prof. Oskar A. Hass, Specialist of chemical lab. and genetic diagnosis, St Anna's Kinderspital Laboratory Vienna, Austria: MAHAK is a centralized organization that operates on the basis of gathered and controllable information and uses research data in the field of pediatric cancer. It is therefore clear that, like other treatment centers, it plays an important role in increasing the rate of recovery in children with cancer.
Dr. Iman Eshghi, pediatric hematologist and oncologist, Iran: Holding this scientific event by MAHAK without relying on governmental funds and resources is really precious. This organization, not only as an NGO but also as a scientific and research center has been focused on improving knowledge and sharing experiences as its great concern. Therefore, we can say that the existence of such organizations in the country is of great importance.
Dr. Mohammad Pedram, pediatric hematologist and oncologist, Iran: MAHAK is a renowned NGO which functions within international frameworks. In addition, the activities of this organization regarding the hematopoietic stem cells transplantation are absolutely laudable.
Dr. Soudabeh Hosseini, PhD holder in laboratory science and medical diagnosis, Iran: After this event, pediatric hematologist and oncologists will stay connected with one another and can easily share their achievements with their colleagues around the world. As a result, more effective treatments will be offered, and eventually, children with cancer will have a better chance of recovery. Therefore, it can be said that MAHAK plays a significant role in treating children with cancer.
Dr. Mohammad Taghi Arzanian, pediatric hematologist and oncologist, Iran: MAHAK has a valuable role in the exchange of knowledge and expertise. It is therefore recommended to host more international academic congresses at student levels so that all students across the country can benefit from the shared information in these events.
Dr. Ali Ehsani Pediatric hematologist and oncologist, Iran: The existence of MAHAK and other alike organizations is absolutely essential in the country's medical treatment system. In addition to being financially and emotionally sponsored, MAHAK provides an opportunity for the presence of national and international professors alongside each other by holding the International Pediatric Oncology Congress.
Dr. Gholamreza Bahoush, hematologist and oncologist, Iran: By holding these congresses MAHAK will help to better introduce Iranian specialists to the international community and provide a platform for effective communication to enhance knowledge and share experiences between them.
Dr. Mohammad Faranoush, pediatric hematologist and oncologist, Iran: MAHAK plays an important role in the treatment of children with cancer in the country. The financial and psychosocial support of this organization makes it possible for children with cancer and their families to focus on treatment and frees them from being concerned about the how to pass the treatment process. In this situation, the only problem is how to deal with the problems of cancer treatment. Hence, sharing the latest information and introducing the treatment methods on different types of blood cancer and lymph node cancer in this congress, obviated the mentioned problem.
Dr. Samineh Alavi, pediatric hematologist and oncologist, Iran: In the course of the past few years, MAHAK in addition to performing its primary role as a charity has also become a scientific center. This scientific event paves the way for cancer treatment. Hence, the continuity and repetition of it and the provision of information from scientific lectures and panels will lead to the promotion of scientific knowledge.
Dr. Behzad Poopak, Ph.D. holder in laboratory sciences and Head of the Association of Ph.D. in Laboratory Sciences, Iran: Holding this congress in MAHAK will increase the confidence in Iranian specialists. In this event, as a classroom, new therapeutic approaches were discussed and scientific achievements in the field of oncology were shared.
Dr. Zohreh Adinehpour, general practitioner, Iran: By holding scientific events such as this pediatric oncology congress, professors and specialists meet each other from around the world. Participating in these events will bring new benefits to cancer treatment.
Dr. Hassan Abolghassemi, Head of Iranian Pediatric Hematology and Oncology Society: Today, people have a huge responsibility for treating children with cancer. MAHAK plays an important role in treating cancer-stricken children. Charities like MAHAK can help improve the conditions of cancer treatment in children.